)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
ImmuPharma
ImmuPharma (IMM) investor relations material
ImmuPharma H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary15 Sep, 2026
Executive summary
Reported an operating loss of £1.1 million for H1 2026, slightly improved from £1.2 million in H1 2025.
Overall loss increased to £4.7 million from £1.9 million due to a £3.36 million finance loss on derivative financial asset revaluation.
Raised £6.47 million in equity funding to support accelerated development of Kapiglucagon and maintain P140 as a priority.
Cash runway expected to extend to at least H2 2028 following fundraising.
Continued progress on P140 and Kapiglucagon development, with focus on scientific, regulatory, and commercial milestones.
Financial highlights
Operating loss for H1 2026: £1.1 million (H1 2025: £1.2 million).
R&D expenses: £0.6 million (H1 2025: £0.7 million); administrative expenses: £0.4 million.
Net loss: £4.7 million (H1 2025: £1.9 million), mainly due to derivative financial asset fair value loss.
Cash balance at 30 June 2026: £0.7 million (30 June 2025: £0.4 million).
Derivative financial asset valued at £2 million, up from £0.6 million a year earlier.
Outlook and guidance
Cash runway projected to last until at least H2 2028.
Focus remains on advancing P140 and Kapiglucagon, with a goal to secure a commercial deal for P140 in 2026.
Continued disciplined development expenditure and partnering strategy.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ImmuPharma
- Advanced P140, reduced losses, and strengthened cash position amid ongoing funding risks.IMM
H2 2025 - Accelerated funding supports P140 licensing and Kapiglucagon's rapid Type 1 diabetes development.IMMInvestor update
- Loss increased on higher R&D, but P140 advances and new funding support future growth.IMMH1 2025
- Operating loss reduced, cash position improved, and late-stage clinical pipeline advanced.IMMH1 2024
- P140 clinical programs advanced, fundraising bolstered liquidity, but going concern risks persist.IMMH2 2023
- Losses narrowed and scientific advances achieved, but funding and going concern risks remain.IMMH2 2024
Next ImmuPharma earnings date
H2 202626 May, 2027
ImmuPharma
Next ImmuPharma earnings date
H2 202626 May, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
ImmuPharma plc is a pharmaceutical company focused on the research, development, and commercialization of novel peptide-based drugs. The company specializes in therapies for autoimmune and inflammatory diseases, with activities spanning early-stage discovery through to clinical development. Its research is supported by collaborations with scientific institutions and licensing partnerships. The company is headquartered in London, United Kingdom, and its shares are listed on the AIM.